A highly-regarded and experienced attorney - with a particular specialism in molecular biology - Stephanie’s clients range from start-ups and university spinouts through to established international corporations, where she is equally comfortable dealing with early-stage research and mature products and portfolios.
She has extensive expertise in both prosecution and oppositions at the EPO and regularly advises on filing and prosecution strategy, as well as oppositions and due diligence investigations. She has also advised on supplementary protection certificate (SPC) strategy in relation to small molecules and biologics and has prosecuted SPC applications both within and outside the UK.
Her experience also spans litigation, including UK and European litigation on behalf of Alnylam Pharmaceuticals concerning the first RNAi therapeutic to gain regulatory approval, in which she led and co-ordinated the technical strategy across all European proceedings and oppositions at the EPO.
Stephanie also has extensive experience in advising SMEs and academic technology transfer departments.
Prior to joining Potter Clarkson in 1997, Stephanie gained valuable industry experience, working for Fisons Pharmaceuticals, then Astra AB, as a research biochemist.
She became a partner in 2004 and is a member of the board of management.